Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Asset Writedowns and Impairment (2024 - 2025)

Indivior Pharmaceuticals has reported Asset Writedowns and Impairment over the past 2 years, most recently at $3.0 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $3.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $19.0 million (up 137.5% YoY), and the annual figure for FY2025 was $19.0 million, up 137.5%.
  • Asset Writedowns and Impairment for Q4 2025 was $3.0 million at Indivior Pharmaceuticals, down from $16.0 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for INDV hit a ceiling of $16.0 million in Q3 2025 and a floor of $1.0 million in Q1 2024.